Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Eptifibatide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 known ✓ | P05106 | 5/20 | 1.00 |
| ▸ | ITGA2B known ✓ | P08514 | 3/20 | 1.00 |
| ▸ | ITGAV | P06756 | 5/20 | 1.00 |
| ▸ | MC3R | P41968 | 5/20 | 0.59 |
| ▸ | MC5R | P33032 | 4/20 | 0.59 |
| ▸ | MC4R | P32245 | 3/20 | 0.59 |
| ▸ | ITGA5 | P08648 | 4/20 | 0.57 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.57 |
| ▸ | ITGB5 | P18084 | 2/20 | 0.57 |
| ▸ | LDLR | P01130 | 9/20 | 0.57 |
| ▸ | PCSK9 | Q8NBP7 | 9/20 | 0.57 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Eptifibatide SCHEMBL18504808 | 1.00 | ITGB3 (1.00) | ITGB3ITGAVITGA2BMC3RMC5R | |
| Eptifibatide SCHEMBL22193879 | 1.00 | ITGB3 (1.00) | ITGB3ITGAVITGA2BMC3RMC5R | |
| Eptifibatide SCHEMBL29353236 | 1.00 | ITGB3 (1.00) | ITGB3ITGAVITGA2BMC3RMC5R | |
| Eptifibatide SCHEMBL16883987 | 1.00 | ITGB3 (1.00) | ITGB3ITGAVITGA2BMC3RMC5R | |
| Eptifibatide SCHEMBL1649793 | 1.00 | ITGB3 (1.00) | ITGB3ITGAVITGA2BMC3RMC5R | |
| Eptifibatide SCHEMBL16884017 | 1.00 | ITGB3 (1.00) | ITGB3ITGAVITGA2BMC3RMC5R | |
| SCHEMBL29356871 | 0.98 | ITGB3 (0.97) | ITGB3ITGAVITGA2BMC3RMC5R | |
| SCHEMBL16883997 | 0.93 | ITGB3 (0.87) | ITGB3ITGAVITGA2BLDLRPCSK9 | |
| SCHEMBL24433345 | 0.93 | ITGB3 (0.86) | ITGB3ITGAVITGA2BMC3RMC5R | |
| SCHEMBL16883930 | 0.91 | ITGB3 (0.84) | ITGB3ITGAVITGA2BMC3RMC5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 4247 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026103722-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF COAGULATION FACTOR XI (FXI) | SHANGHAI ARGO BIOPHARMACEUTICAL CO., LTD. (CN) | 2026-05-21 | — | — | WO | claimed |
| EP-4705465-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF COAGULATION FACTOR XI (FXI) | Shanghai Argo Biopharmaceutical Co., Ltd. (CN) | 2026-03-11 | — | — | EP | claimed |
| US-20240390364-A1 | Novel Pyridine Compositions and their use in methods for preventing or treating diseases, disorders and conditions | REID CHRISTOPHER BRIAN (US) | 2024-11-28 | — | — | US | claimed |
| WO-2024240058-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF COAGULATION FACTOR XI (FXI) | SHANGHAI ARGO BIOPHARMACEUTICAL CO., LTD. (CN) | 2024-11-28 | — | — | WO | claimed |
| US-20240058455-A1 | BIOORTHOGONAL LINKERS AND REACTIONS | THE GENERAL HOSPITAL CORPORATION | 2024-02-22 | — | — | US | claimed |
| US-20220403036-A1 | P-SELECTIN INHIBITOR, COMPOSITIONS THEREOF AND METHODS OF USE THEREOF | THE JOHNS HOPKINS UNIVERSITY | 2022-12-22 | — | — | US | claimed |
| WO-2022072949-A2 | BIOORTHOGONAL LINKERS AND REACTIONS | THE GENERAL HOSPITAL CORPORATION (US) | 2022-04-07 | — | — | WO | claimed |
| US-20210179577-A1 | AROMATIC SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF ISCHEMIC STROKE | BAYER AKTIENGESELLSCHAFT (DE) | 2021-06-17 | — | — | US | claimed |
| US-20210109110-A1 | PATIENT ASSESSMENT METHOD | UNIVERSITY OF COPENHAGEN (DK) | 2021-04-15 | — | — | US | claimed |
| EP-3764988-A1 | GEL-FORMING POLYPEPTIDES | Adepthera LLC (US) | 2021-01-20 | — | — | EP | claimed |
| WO-2002019935-A1 | METHOD AND SYSTEM FOR ANTICOAGULANT DOSE REVISION | THE RXFILES CORPORATION (US) | 2002-03-14 | — | — | WO | claimed |
| US-6344028-B1 | Replenishable stent and delivery system | BOSTON SCIENTIFIC CORPORATION | 2002-02-05 | — | — | US | claimed |
| WO-2001092283-A2 | COBALAMIN COMPOUNDS USEFUL AS CARDIOVASCULAR AGENTS AND AS IMAGING AGENTS | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2001-12-06 | — | — | WO | claimed |
| WO-2001049311-A1 | PHARMACEUTICAL FORMULATION COMPOSED OF A POLYMER BLEND AND AN ACTIVE COMPOUND FOR TIME-CONTROLLED RELEASE | RUTGERS, THE STATE UNIVERSITY (US) | 2001-07-12 | — | — | WO | claimed |
| WO-2001049249-A2 | PHARMACEUTICAL FORMULATION FOR REGULATING THE TIMED RELEASE OF BIOLOGICALLY ACTIVE COMPOUNDS BASED ON A POLYMER MATRIX | RUTGERS, THE STATE UNIVERSITY (US) | 2001-07-12 | — | — | WO | claimed |
| EP-1090132-A1 | METHODS FOR PRODUCTION OF RECOMBINANT POLYPEPTIDES | PPL Therapeutics (Scotland) Limited (GB) | 2001-04-11 | — | — | EP | claimed |
| EP-1062229-A1 | PHARMACOLOGICALLY ACTIVE PEPTIDE CONJUGATES HAVING A REDUCED TENDENCY TOWARDS ENZYMATIC HYDROLYSIS | Zealand Pharmaceuticals A/S (DK) | 2000-12-27 | — | — | EP | claimed |
| WO-2000000625-A1 | METHODS FOR PRODUCTION OF RECOMBINANT POLYPEPTIDES | PPL THERAPEUTICS (SCOTLAND) LIMITED (GB) | 2000-01-06 | — | — | WO | claimed |
| WO-1999046283-A9 | PHARMACOLOGICALLY ACTIVE PEPTIDE CONJUGATES HAVING A REDUCED TENDENCY TOWARDS ENZYMATIC HYDROLYSIS | ZEALAND PHARMACEUTICALS A S (DK) | 1999-11-18 | — | — | WO | claimed |
| WO-1999046283-A1 | PHARMACOLOGICALLY ACTIVE PEPTIDE CONJUGATES HAVING A REDUCED TENDENCY TOWARDS ENZYMATIC HYDROLYSIS | ZEALAND PHARMACEUTICALS A/S (DK) | 1999-09-16 | — | — | WO | claimed |